Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Liu

Showing results (151-160 of 187) with videos related to

Pageof 19
Sort By:
The Oncologist|April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)Adel Mandl, Ruizhe Chen, Satya Das, et al.
Nature Reviews. Clinical Oncology|March 24, 2021
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
Nature Reviews. Clinical Oncology|March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2023
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposideStephen V Liu, Tony S K Mok, Barzin Y Nabet, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Molecular Cancer Therapeutics|September 14, 2021
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung CancerJulia Judd, Nagla Abdel Karim, Hina Khan, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Critical Reviews in Oncology/Hematology|October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trialsDaniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Pageof 19

Showing results (151-160 of 187) with videos related to

Sort By:
Pageof 19
The Oncologist|April 12, 2026
Phase 2 Study of Cabozantinib (XL184) with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas (ETCTN10315)Adel Mandl, Ruizhe Chen, Satya Das, et al.
Nature Reviews. Clinical Oncology|March 24, 2021
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
Nature Reviews. Clinical Oncology|March 16, 2021
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsAakash Desai, Justin F Gainor, Aparna Hegde, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2023
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposideStephen V Liu, Tony S K Mok, Barzin Y Nabet, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Molecular Cancer Therapeutics|September 14, 2021
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung CancerJulia Judd, Nagla Abdel Karim, Hina Khan, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
Critical Reviews in Oncology/Hematology|October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trialsDaniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Pageof 19